Skip to main content
Zhejiang Shengda Bio-Pharm Co.,Ltd. logo

Zhejiang Shengda Bio-Pharm Co.,Ltd. — Investor Relations & Filings

Ticker · 603079 ISIN · CNE100002W43 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,082 across all filing types
Latest filing 2026-05-18 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603079

About Zhejiang Shengda Bio-Pharm Co.,Ltd.

https://www.sd-pharm.com/index_en.html

Zhejiang Shengda Bio-Pharm Co., Ltd. specializes in the research, development, production, and global distribution of vitamins and biological products. The company is a leading global manufacturer of Biotin (Vitamin H) and Folic Acid (Vitamin B9), serving the pharmaceutical, food additive, and animal feed sectors. Its product portfolio includes various vitamin derivatives and pharmaceutical intermediates produced under strict quality management systems, including GMP and ISO certifications. By leveraging advanced fermentation and chemical synthesis technologies, the company provides high-purity ingredients to international markets. Operations focus on sustainable manufacturing processes and continuous innovation in biotechnology to meet the evolving demands of the global life sciences sector.

Recent filings

Filing Released Lang Actions
浙江圣达生物药业股份有限公司关于董事长代行董事会秘书职责的公告
Board/Management Information Classification · 95% confidence The document is a brief public notice announcing that the company’s chairman will temporarily perform the duties of the board secretary after the previous secretary’s departure. This is clearly an announcement of a change in senior management roles, fitting the Board/Management Information category.
2026-05-18 Chinese
浙江天册律师事务所关于浙江圣达生物药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 90% confidence The document is a legal opinion letter (‘法律意见书’) issued by an external law firm regarding the legality of convening, attendance, procedures, and voting at the company’s 2025 annual shareholders’ meeting. It is not the AGM presentation itself, nor a proxy solicitation, nor the formal vote-results announcement by the company, but rather an attestation/certification by counsel. Under the Certification Rule, such attestations fall into the Regulatory Filings fallback category (RNS).
2026-05-18 Chinese
浙江圣达生物药业股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 93% confidence The document is the official announcement of the 2025 Annual General Meeting resolutions of Zhejiang Shengda Bio-Pharma Co., Ltd., detailing attendance, each proposal voted on, and the vote counts and percentages. It is a declaration of voting results for an AGM, matching the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-18 Chinese
浙江圣达生物药业股份有限公司2025年年度股东会会议材料
AGM Information Classification · 98% confidence The document is titled “2025年年度股东会会议材料” and contains the full set of agenda items, proposals, board reports, financial statements, and background materials prepared for the company’s 2025 Annual General Meeting (AGM). It is not the standalone annual report or an earnings release, but the meeting materials specifically for the AGM itself. Therefore, it matches the “AGM Information (AGM-R)” category.
2026-05-11 Chinese
中信建投证券股份有限公司关于浙江圣达生物药业股份有限公司2025年持续督导年度报告书
Regulatory Filings
2026-05-06 Chinese
浙江圣达生物药业股份有限公司2026年第一季度主要经营数据公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2026年第一季度主要经营数据公告" which translates to "2026 First Quarter Main Operating Data Announcement." It provides detailed quarterly operational data including production volume, sales volume, revenue, price changes of main products and raw materials, and geographic sales distribution. The document explicitly states it is for the first quarter of 2026 and includes substantive financial and operational data, although unaudited. The length is 1345 characters, which is short but contains actual financial data and analysis, not just a notice or announcement of a report. This fits the definition of an Interim / Quarterly Report (IR), which covers a period shorter than a full fiscal year and contains substantive financial data and analysis. It is not a simple announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is IR with high confidence. Q1 2026
2026-04-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.